RT Journal Article
SR Electronic
T1 Unique proteome signatures in ICU patients with COVID-19 and delirium: an observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.09.24317145
DO 10.1101/2024.12.09.24317145
A1 Edel, Andreas
A1 Sreekanth, Jayanth
A1 Kurth, Florian
A1 Ralser, Markus
A1 Demichev, Vadim
A1 Mülleder, Michael
A1 Blanc, Eric
A1 Spies, Claudia
YR 2024
UL http://medrxiv.org/content/early/2024/12/12/2024.12.09.24317145.abstract
AB Background Delirium is common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology.Methods This prospective observational satellite study aims to investigate the proteome signatures of COVID-19 ICU patients, comparing those with delirium to those without. This study was conducted in ICUs of a university hospital between March 2020 and September 2021. ICU patients of legal age with a positive SARS-CoV-2 test were screened daily for oversedation and delirium. Blood samples were taken thrice a week. 457 samples were analyzed using data-independent acquisition mass spectrometry to determine protein levels. A mixed-effects logistic regression model was developed to identify proteins significantly influenced by delirium, accounting for sex and age as confounders. This model also aimed to determine proteins that were either up- or downregulated in association with delirium. Additionally, an enrichment analysis was conducted to examine the biological pathways linked to these delirium-associated proteins.Results Out of 360 ICU patients, 69 were analyzed for protein profiling. Out of these 69 patients, 42 patients (60.9%) had delirium on ICU admission, and 27 (39.1%) did not. Based on the multivariate model, the analysis of 204 proteins unfolded 125 (61.3%) to be differentially expressed. In total, 80.8% (n=101) of these 125 proteins were associated with delirium. Of these, 10 proteins were uniquely associated with delirium and were not significant in the multivariate model (SERPING1, SERPINA7, HP, TGFBI, CD5L, IGHV3-7, IGHV1-46, IGHV3-15, IGHV3-23, and “IGHV4-34;IGHV4-38-2”). In the univariate model for delirium, six out of 111 significant proteins showed increased expression with a log2FC > 0.5: PIGR, MST1, LBP, CRP, SAA1, and “SAA1;SAA2”; while three showed decreased expression with a log2FC < - 0.5: HP, PPBP, and “HP;HPR”. The enrichment analysis of delirium-influenced proteins revealed three significant pathways: “Network map of SARS-CoV-2 signaling” (M42569/WP5115), “Acute inflammatory response” (M10617), and “Regulation of defense response” (M15277).Conclusion We identified a unique proteomic signature in COVID-19 ICU patients with delirium, including up- and downregulated proteins. These findings may provide potential biomarker candidates for the assessment of delirium risk and its underlying causes. These findings could be a further step towards the development of personalized, causative treatments for delirium and its monitoring in the ICU.Trial registration The study was retrospectively registered in the German Clinical Trials Register on May 13, 2020 (DRKS00021688).Competing Interest StatementAndreas Edel declares that his institution received payments or honoraria for lectures and expert testimony from Gilead Sciences GmbH and Draeger Medical Deutschland GmbH. Andreas Edel hold shares of BioNTech and Novavax (less than 5000 Euro). Andreas Edel declares to be a member of the German Society of Anaesthesiology and Intensive Care Medicine (DGAI) and participate in the DGAI Round Table on Tele ICU. Additionally, he collaborates in the section on Metabolism and Nutrition of the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI). He holds memberships in several other organizations, including the German Sepsis Society (DSG), the European Society of Intensive Care Medicine (ESICM), the European Society of Anaesthesiology and Intensive Care (ESAIC), the German Society for Nutritional Medicine (DGEM), and the European Society for Clinical Nutrition and Metabolism (ESPEN), although he is not actively involved in committee work in these organizations. Jayanth Sreekanth declares that he has no competing interests. Florian Kurth received a research grant from GSK Inc. for unrelated work. He has also received honoraria for lectures from Pfizer Inc. and was supported by Gilead Inc. to attend a conference. Markus Ralser is founder, CSO and shareholder of Elitptica Ltd. There is no relationship of this role and the current work. Vadim Demichev reports receiving funding from the German Federal Ministry of Education and Research (BMBF) under research grant 161L0221 in support of this manuscript and declares his shareholder interest in Aptila Biotech GmbH. Michael Muelleder reports receiving funding from the German Federal Ministry of Education and Research (BMBF) under research grant 16LW0239K in support of this manuscript. He is a consultant and shareholder at Eliptica Ltd. He also received financial support from Thermo Scientific to attend the HUPO 2024 conference, which covered conference fees for a presentation given at their on site User Meeting. Additionally, he holds patents planned, issued, or pending in association with Inoviv, Inc., including a joint patent for a COVID 19 Multiple Reaction Monitoring (MRM) panel. Eric Blanc declares that he has no competing interests. Claudia Spies reports grants from The European Commission Horizont Europa, German Federal Joint Committee (Gemeinsamer Bundesausschuss GBA), German Federal Ministry of Education and Research (BMBF), Philips Electronics Nederland BV, Max Planck Society, Sintetica GmbH, Dr. F. Koehler Chemie GmbH, Georg Thieme Verlag, German Federal Ministry for Economic Affairs and Climate Action (BMWI), European Society of Anesthesiology and Intensive Care, Stifterverband (non profit society promoting science and education), Charite internal university grants, Einstein Foundation Berlin, German Aerospace Center (Deutsches Zentrum fuer Luft und Raumfahrt e.V. DLR) and German Research Society (Deutsche Forschungsgemeinschaft) during the conduct of the study. In addition, Claudia Spies has different patents and an unpaid leadership or fiduciary role in association of the Scientific Medical Societies in Germany (AMWF), German Research Foundation (Deutsche Forschungsgemeinschaft), German National Academy of Sciences Leopoldina (Deutsche Akademie der Naturforscher Leopoldina e. V.), Berlin Medical Society (Berliner Medizinische Gesellschaft), ESICM European Society of Intensive Care Medicine, ESAIC European Society of Anaesthesiology and Intensive Care, German Society of Anaesthesiology and Intensive Care Medicine (Deutsche Gesellschaft fuer Anaesthesiologie und Intensivmedizin DGAI), German Interdisciplinary Association for Intensive Care and Emergency Medicine(Deutsche Interdisziplinaere Vereinigung fuer Intensiv und Notfallmedizin DIVI) and German Sepsis Foundation (Deutsche Sepsis Stiftung). Claudia Spies has participated on Data Safety Board or Advisory boards for Prothor, Takeda Pharmaceutical Company Limited and Lynx Health Science GmbH. Clinical Protocols https://pmc.ncbi.nlm.nih.gov/articles/PMC7293426/ Funding StatementThe study was further supported by the German Federal Ministry of Education and Research (NaFoUniMedCovid19 NUM NAPKON, NUM COVIM, FKZ: 01KX2021 and PROVID FKZ: 01KI20160A) as well as BIH and Charite internal research funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Charite-Universitaetsmedizin Berlin under the reference number EA2/066/20.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analyzed during the current satellite study are available from the corresponding author on reasonable request. The table of primary protein quantities together with the corresponding metadata, has been formerly published at https://doi.org/10.1371/journal.pdig.0000007. Additionally, the mass spectrometry proteomics data have been submitted to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository and assigned the dataset identifier PXD029009. https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD029009 A2MAlpha-2-Macroglobulin (Fetuin-A)APOMApolipoprotein MAPOMApolipoprotein MARDSAcute Respiratory Distress SyndromeBPSBehavioral Pain ScaleBMIBody Mass IndexC1INHC1 InhibitorC7Complement Component 7CAM-ICUConfusion Assessment Method for the ICUCCACanonical Correlation AnalysisCD14Cluster of Differentiation 14CD5LCD5 Antigen-Like ProteinCRRTContinuous Renal Replacement TherapyCRPC-Reactive ProteinCST3Cystatin CCOVID-19Coronavirus Disease 2019CPOTCritical Care Pain Observation ToolCXCL1C-X-C Motif ChemokineECMOExtracorporeal Membrane OxygenationF2Coagulation Factor II (Prothrombin)F12Coagulation Factor XII (Hageman Factor)FETUBFetuin-BFSAPFactor VII Activating ProteaseGCSGlasgow Coma ScaleHAHyaluronic AcidHABP2Hyaluronan-Binding Protein 2HDLHigh-Density LipoproteinHGFLHepatocytes Growth Factor-Like ProteinHMWKHigh Molecular Weight KininogenHPHaptoglobin“HP; HPR”Haptoglobin and Haptoglobin-Related ProteinHPXHemopexinICUIntensive Care UnitIgImmunoglobulinIGFALSInsulin-Like Growth Factor-Binding Protein, Acid Labile SubunitIGHA1Immunoglobulin Heavy Constant Alpha 1IGHVImmunoglobulin Heavy Chain Variable regionITIH3Inter-Alpha-Trypsin Inhibitor Heavy Chain 3ITIH4Inter-Alpha-Trypsin Inhibitor Heavy Chain 4IQRInterquartile RangeKKSKallikrein-Kinin-SystemKLKB1Kallikrein B, Plasma (Fletcher Factor) 1KNG1Kininogen-1LBPLipopolysaccharide-Binding ProteinLMWKLow Molecular Weight KininogenLog2FCLog2 Fold-ChangeMSPMacrophage Stimulating ProteinMST1Macrophage Stimulating 1NTINon-Thyroidal IllnessNRSNumerical Rating ScalePBPPlatelet Basic ProteinPIGRPolymeric Immunoglobulin ReceptorPPBPPro-Platelet Basic ProteinPRG4Proteoglycan 4RASSRichmond Agitation Sedation ScaleRONReceptor Tyrosine Kinase Recepteur D’origine NantaisRT-PCRReverse Transcriptase Polymerase Chain ReactionSAA(1) Serum Amyloid A (1)“SAA1; SAA2”Serum Amyloid A1 and Serum Amyloid A2SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SERPINA7Serpin Family A Member 7 (Thyroxin-Binding Globulin)SERPING1Serpin Family G Member 1 (C1 Inhibitor)SOFASequential Organ Failure AssessmentSOPStandard Operating ProcedureTBGThyroxin-Binding GlobulinTGFBITransforming Growth Factor-Beta-Induced ProteinTGF-βTransforming Growth Factor – βT3TriiodothyronineT4ThyroxineTSHThyroid-Stimulating HormoneWHOWorld Health Organization